InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities
InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities
09/04/20, 2:13 AM
Money raised
$19 million
Round Type
series a
InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced the completion of its Series A+ financing of 130M RMB (~US$19Million). The financing was led by Ennovation Ventures and China Growth Capital and followed by InnoMed Capital and Grand Yangtze Capital.
Company Info
Additional Info
InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and being a China based biotech company with global impact. We have built translational medicine and clinical development team across Shanghai, Beijing, Nanjing, United States, Canada and Australia. We have built a highly differentiated pipeline and established partnership with various multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim.